Blackstone and TPG Eye $17 Billion Hologic Acquisition
Blackstone and TPG are in advanced talks to acquire medical device maker Hologic for over $17 billion, potentially becoming one of 2025's largest private equity deals.
/ 207 items
#Healthcare↓
Viridian Therapeutics Gets Double Buy Rating After Roche's Weak TED Results
Jefferies and Wedbush maintain Buy ratings on Viridian Therapeutics as Roche's thyroid eye disease drug shows weaker results than Viridian's veligrotug therapy.
Jefferies Boosts Atai Life Sciences Price Target to $10 on FDA Breakthrough Win
Jefferies raises Atai Life Sciences price target to $10 following FDA Breakthrough Therapy Designation for depression drug BPL-003, citing 72% approval rate for BTD drugs.
Elfabrio Every-4-Weeks Dosing Rejected by EMA Committee
Chiesi and Protalix received a negative CHMP opinion for Elfabrio's dosing regimen. The companies remain committed to reducing the treatment burden for Fabry disease patients.
Artiva Biotherapeutics Stock Soars: Wedbush Raises Price Target to $23 on Breakthrough RA Treatment
Wedbush upgrades Artiva Biotherapeutics price target to $23 citing FDA Fast Track for AlloNK therapy targeting refractory rheumatoid arthritis with potential 2026 pivotal trial.
FDA Fast-Tracks First Vaping Cessation Treatment for Cytisinicline
Achieve Life Sciences receives FDA's National Priority Voucher for cytisinicline, potentially the first approved treatment to help people quit vaping and e-cigarettes.